A Study of the Safety and Efficacy of Sitagliptin Addition During Metformin Up-titration (MK-0431-848)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 458 participants.
Also called NCT02791490
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 458 participants
- Sponsor
- Registry
-
NCT02791490 -
2015-004224-59
-
- Other papers using this trial's data
- Double-blind, randomized clinical trial assessing the efficacy and safety of early initiation of sitagliptin during metformin uptitration in the treatment of patients with type 2 diabetes: The CompoSIT-M study
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Not reported
- Registry status
- Completed
Technical summary
Registry record NCT02791490. Randomized; double masking; primary purpose treatment. Start 2016-06-16 (actual); primary completion 2018-02-01 (actual). Results posted on 2019-02-28.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of the Safety and Efficacy of Sitagliptin Addition During Metformin Up-titration (MK-0431-848)
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Sitagliptin
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Metformin IR
- Lead sponsor
- Merck Sharp & Dohme LLC
Record details
- Record id
cardio:ct-nct02791490- Content hash
88131fb3d8bde6c9911fea8c5da6393a4f9f1ddc92e43340fbb50a277fec9c38